NCT01970358View on ClinicalTrials.gov

A Phase I Study with a Personalized NeoAntigen Cancer Vaccine in Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

June 30, 2018

Conditions
Melanoma
Interventions
BIOLOGICAL

Poly-ICLC

BIOLOGICAL

Peptides

Trial Locations (2)

02115

Brigham and Women's Hospital, Boston

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Patrick Ott, MD, PhD

OTHER

NCT01970358 - A Phase I Study with a Personalized NeoAntigen Cancer Vaccine in Melanoma | Biotech Hunter | Biotech Hunter